Evidence map›Paper›PMID 42006413›Full record

ArticleAmerican journal of preventive cardiology2026

Cardiovascular outcomes with icosapent ethyl by burden of standard modifiable cardiovascular risk factors in REDUCE-IT.

Rahul Aggarwal, Deepak L Bhatt, Michael Miller, Christie M Ballantyne, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Jean-Claude Tardif, Matthew J Budoff, Gemma A Figtree and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rahul AggarwalBrigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.
Deepak L BhattMount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Michael MillerDepartment of Medicine, Crescenz Veterans Affairs Medical Center and University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Christie M BallantyneDepartment of Medicine, Baylor College of Medicine, and the Texas Heart Institute, Houston, TX, USA.
Eliot A BrintonUtah Lipid Center, Salt Lake City, UT, USA.
Terry A JacobsonLipid Clinic and Cardiovascular Risk Reduction Program, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Steven B KetchumAmarin Pharma, Inc., Bridgewater, NJ, USA.
Jean-Claude TardifMontreal Heart Institute, Université de Montréal, Montreal, Canada.
Matthew J BudoffLundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, USA.
Gemma A FigtreeThe University of Sydney, Sydney, NSW, Australia.
Ph Gabriel StegUniversité Paris-Cité, INSERM-UMR1148, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, French Alliance for Cardiovascular Trials, Paris, France.
REDUCE-IT Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CardiovascularIcosapent ethylStandard modifiable cardiovascular risk factors

Identifiers

PMID42006413
PMCPMC13084092

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.